Skip to main content

Emerging Immunotherapeutic Agents

Guest Editors:
Micheal Kalos
Ignacio Melero
Laszlo Radvanyi

This series is the culmination of a special call for papers that was conducted in early 2018. These original research articles add to the journal’s scope by addressing basic biophysical properties, synthesis and manufacturing, novel mechanisms of action, preclinical safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and regulatory information on new immunotherapy agents and their combinations. They focus on new agents that are intended to begin, or are undergoing, clinical development, while also including molecules that are in advanced clinical development or approved.

  1. The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-gene signature that measures a pre-existing but suppressed adaptive immune response within tumors. The TIS has been shown to enric...

    Authors: Patrick Danaher, Sarah Warren, Rongze Lu, Josue Samayoa, Amy Sullivan, Irena Pekker, Brett Wallden, Francesco M. Marincola and Alessandra Cesano
    Citation: Journal for ImmunoTherapy of Cancer 2018 6:63
    Content type: Research article Published on:

  2. Pixatimod (PG545) is a novel clinical-stage immunomodulatory agent capable of inhibiting the infiltration of tumor-associated macrophages (TAMs) yet also stimulate dendritic cells (DCs), leading to activation ...

    Authors: Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang and Keith Dredge
    Citation: Journal for ImmunoTherapy of Cancer 2018 6:54
    Content type: Research article Published on:

  3. TGFβ signaling plays a pleotropic role in tumor biology, promoting tumor proliferation, invasion and metastasis, and escape from immune surveillance. Inhibiting TGFβ’s immune suppressive effects has become of ...

    Authors: Rikke B. Holmgaard, David A. Schaer, Yanxia Li, Stephen P. Castaneda, Mary Y. Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R. Manro, Philip W. Iversen, David Surguladze, Gerald E. Hall, Ruslan D. Novosiadly, Karim A. Benhadji, Gregory D. Plowman, Michael Kalos…
    Citation: Journal for ImmunoTherapy of Cancer 2018 6:47
    Content type: Research article Published on:

  4. Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patie...

    Authors: Michael Lattanzi, Joseph Han, Una Moran, Kierstin Utter, Jeremy Tchack, Rachel Lubong Sabado, Russell Berman, Richard Shapiro, Hsin-Hui Huang, Iman Osman, Nina Bhardwaj and Anna C. Pavlick
    Citation: Journal for ImmunoTherapy of Cancer 2018 6:38
    Content type: Research article Published on:

  5. Modulation of the PD-1/PD-L1 axis through antagonist antibodies that block either receptor or ligand has been shown to reinvigorate the function of tumor-specific T cells and unleash potent anti-tumor immunity...

    Authors: Yiwen Li, Carmine Carpenito, George Wang, David Surguladze, Amelie Forest, Maria Malabunga, Mary Murphy, Yiwei Zhang, Andreas Sonyi, Darin Chin, Douglas Burtrum, Ivan Inigo, Anthony Pennello, Leyi Shen, Laurent Malherbe, Xinlei Chen…
    Citation: Journal for ImmunoTherapy of Cancer 2018 6:31
    Content type: Research article Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2018 6:45